RxDoctor Payments Data

Tina Rentmeester, NP

Nurse Practitioner · Milwaukee, WINPI 1336204908

Payments from drug & device makers

$939in general payments, 2019–2025

Across 33 payments — averaging $28.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$140
  • Boston Scientific$128
  • E.r. Squibb & Sons, L.L.C.$119
  • Novo Nordisk$110
  • Johnson & Johnson$91
  • Pfizer$86
  • plus $264 from 7 others

What the payments were for

  • Food & beverage$939100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$939 in reported general payments places this provider in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$33,031
Medicare patients
251
Services billed
601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan246$318,355
JardianceEmpagliflozin166$198,466
EliquisApixaban138$158,409
FarxigaDapagliflozin Propanediol118$134,038
Repatha SureclickEvolocumab58$51,064
BrilintaTicagrelor30$25,607
Metoprolol Succinate629$8,441
DapagliflozinDapagliflozin Propanediol24$7,169
Bumetanide164$6,588
Praluent PenAlirocumab11$5,788
Ezetimibe179$3,302
Rosuvastatin Calcium274$3,288
Atorvastatin Calcium420$3,156
Ranolazine ErRanolazine34$2,931
Spironolactone413$2,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$140$318,355246 claims
Boehringer IngelheimJardiance$42$198,466166 claims
AstraZenecaFarxiga, Brilinta$40$159,645148 claims
PfizerEliquis$86$158,409138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →